Eduard Garcia is the Founder and Director of AxioTechBio, a European market access and execution platform specialising in commercial representation and structured partnerships for companies in biotechnology, genomics, and digital health. AxioTechBio operates across France, Spain, and the Nordic markets, supporting technology providers navigating institution‑driven environments.

With an academic background in Veterinary Medicine and a Master’s in Marketing Management, Eduard combines strong scientific literacy with senior-level experience in market access, commercial execution, and strategic representation across complex life sciences, healthcare, and research ecosystems.

Through AxioTechBio, Eduard acts as a permanent local interlocutor for European and international technology companies seeking to enter, structure, and scale within institutional markets — including public healthcare systems, research organisations, and innovation networks. His work focuses on access, positioning, and execution: identifying the right institutional and industrial partners, structuring market entry pathways, and facilitating commercial agreements aligned with national procurement and regulatory frameworks.

AxioTechBio operates strictly as an execution and access layer — not a laboratory, CRO, or technical service provider. This clear separation of innovation risk from market execution enables institutional credibility, procurement intelligence, and relationship‑driven engagement on the ground.

Eduard’s approach is grounded in long‑term value creation, selective non‑competing partnerships, and the translation of high‑value technological innovation into sustainable, real‑world adoption across European markets.